Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy versus chemotherapy alone as first-line treatment for first recurrence of cervical cancer
ChiCTR1800017846Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in Cervical Cancer (CC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800017846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017846.